Navigation Links
A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
Date:5/7/2008

PARSIPPANY, N.J., May 7 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare, marketer of the leading smoking cessation products including Nicorette(R) gum, NicoDerm(R) CQ(R) patch, and Commit(R) lozenge, applauds the release of the updated 2008 U.S. Public Health Service (PHS) Guideline on Treating Tobacco Use and Dependence. Too many smokers lower their chances of quitting by relying on cold turkey approaches to become tobacco-free. The Guideline is an important validation of the need for clinicians to recommend the use of effective tobacco dependence counseling and medication. The Guideline reflects considerable progress in tobacco cessation research over the past decade to help identify the most effective strategies at reducing tobacco dependence.

We believe the 2008 update is of particular significance as it includes the addition of the Commit nicotine lozenge which can reliably increase long-term smoking abstinence. The Commit lozenge is approved by the U.S. Food and Drug Administration (FDA) to help withdrawal symptoms and cravings associated with quitting smoking, has a groundbreaking dosage selector (Time to First Cigarette) so a smoker can choose the strength that's right for them and provides low, safe doses of nicotine to ease withdrawal from cigarettes.

The updated Guideline reflects the distillation of thousands of research articles, and continues to recommend nicotine replacement products (NRT), such as Nicorette gum and NicoDerm CQ patch, as a first-line therapy for quitting, as they "increase significantly rates of long-term smoking abstinence."(1)

GlaxoSmithKline's NRT brands offer a step-down therapy to help smokers break their dependence on tobacco and safely wean off nicotine. Clinical trials have demonstrated that these brands double a smoker's chances of quitting versus placebo.(2) They are extensively proven to significantly reduce cravings and other withdrawal symptoms during quitting, allowing smokers to focus on behavior change. More than 110 clinical trials involving more than 40,000 participants and extensive consumer use over more than 20 years have proven the safety and efficacy of NRT when used as directed.(3)

Since becoming available without a prescription in 1996, GSK's NRT smoking cessation brands have helped millions of people around the world quit smoking and, as a result, have significantly reduced their exposure to the risks of cancer and other smoking-related diseases.(4)

GSK Consumer Healthcare offers smokers a variety of customized quit-smoking resources, including tools and information at http://www.Way2Quit.com, free proven tailored quit plans through http://www.CommittedQuitters.com and free access to GSK-certified stop-smoking counselors weekdays at 1-877-NO-ASHES where a smoker can develop an individualized support plan and receive customized tips from experts.

Quitting smoking is the most important step smokers can take to improve their health -- and it's also one of the most difficult. By developing innovative new products and support systems to improve the quit experience, GSK Consumer Healthcare is working to inspire and enable every smoker to quit.

(1) 2008 U.S. Public Health Service Guideline: Treating Tobacco Use and

Dependence; early draft released in October 2007.

(2) Fiore MC, Bailey WC, Cohen SJ, et al. Treating Tobacco Use and

Dependence. Clinical Practice Guideline. Rockville, MD.

(3) Stead LF, Perera R, Bullen C,Mant D, Lancaster T. Nicotine replacement

therapy for smoking cessation. Cochrane Database of Systematic Reviews

2008, Issue 1. Art. No.: CD000146. DOI:

10.1002/14651858.CD000146.pub3.

(4) Centers for Disease Control and Prevention. Use of FDA-approved

pharmacologic treatments for tobacco dependence. Morbidity and

Mortality Weekly Report 2000; 49: 665-668.


'/>"/>
SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Statement by UHW President Sal Rosselli on SEIU Threat to Sue UHW Leaders
2. Pelosi Statement on Cover the Uninsured Week
3. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
4. Statement by H.E. Jakaya Mrisho Kikwete, President of the United Republic of Tanzania, and Chairman of the African Union, in Response to UN-SG Call to Action on Malaria
5. AHIP Statement on Senate Passage of the Genetic Information Nondiscrimination Act
6. SEIU RN Dian Palmer Calls on AFL-CIO Head John Sweeney to Review Video From Dearborn Protest, Retract Statement Accepting CNA Distortions
7. CNA/NNOC Statement on Restraining Order Against SEIU: Threats, Harassment and Stalking of RNs Remain Out of Bounds
8. Statement: Congress Should Include the Physician Self-Referral Provision in the Farm Bill for Patients and Communities
9. Statement From Larry Minnix, President & CEO, American Association of Homes and Services for the Aging (AAHSA) on the Senate Special Committee on Aging Hearing, Caring for Our Seniors: How Can We Support the Frontlines?
10. Statement by SEIU International President Andy Stern Regarding CNA Temporary Restraining Order
11. Statement of the American Diabetes Association Supporting Federal Courts Ruling on New York City Proposal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... ... opioid overdose deaths now claim the lives of 62 Americans each day.(1) Yet ... against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus ...
(Date:4/24/2017)... ANGELES, CA (PRWEB) , ... April 24, 2017 , ... ... picture is worth a thousand words. The good news for single women is that ... for Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling ...
(Date:4/24/2017)... ... ... “Reflections of God’s Work”: an enlightening collection of life lessons leading each ... published author, Jerri Broglin, a survivor of great loss who gained insight on how ... for those searching for answers, as we are finding the answers that are so ...
(Date:4/24/2017)... NC and Seattle, WA (PRWEB) , ... April ... ... utilized by 75+ leading lifestyle brands, work wear distributors and International relief organizations ... they can carry. The company also offers lifestyle and work wear collections via ...
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year since ... $394.9 billion. The consequences of rapid innovation and growth are often neglected in ... it is every business and individual’s job to give something back to the planet ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: